UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2004
Ocular Sciences, Inc.
Delaware
(State or other jurisdiction of incorporation)
| 0-22623 | 94-2985696 | |
| (Commission File Number) | (IRS Employer Identification No.) |
| 1855 GATEWAY BOULEVARD, SUITE 700, | ||
| CONCORD, CALIFORNIA | 94520 | |
| (Address of principal executive offices) | (Zip Code) |
(925) 969-7000
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
| Item 7: Financial Statements and Exhibits | ||||||||
| Item 12: Results of Operations and Financial Condition | ||||||||
| SIGNATURE | ||||||||
| Exhibit Index | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 7: Financial Statements and Exhibits.
(c) Exhibits.
| Exhibit No. |
Document |
|
99.1
|
Press release issued by Ocular Sciences, Inc. on July 28, 2004* |
*This exhibit is intended to be furnished and shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Item 12: Results of Operations and Financial Condition.
On July 28, 2004, Ocular Sciences, Inc. (the “Company”) announced its results of operations and financial condition as of and for the quarter ended June 30, 2004 in a press release that is attached hereto as Exhibit 99.1.
The information in this Report, including the Exhibit 99.1 attached hereto, is furnished pursuant to Items 9 and 12 of this Form 8-K. Consequently, it is not deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934 or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K.
The Company’s earnings release contains non-GAAP financial measures. Pursuant to the requirements of Regulation G, the Company has provided reconciliations within the press release of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
Adjusted operating income, net income and earnings per share data, and free cash flow data, is presented in the earnings release. The operating income, net income and earnings per share data is adjusted to exclude restructuring and related charges that impacted the Company’s results of operations. Specifically, the Company has excluded restructuring and related charges associated with the manufacturing transition program announced in December 2002 that the Company expects to complete in 2004. The Company’s management uses this information excluding these charges in evaluating results of the continuing operations of the Company and believes that this information provides investors with valuable insight into the underlying results of operations of the Company and facilitates comparison between the Company and other companies. The Company also believes that the use of a free cash flow measure is appropriate information because it provides investors and others with a measure of cash generated by the Company which could be available to fund on going operations, repay creditors and generate returns to shareholders.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OCULAR SCIENCES, INC. |
||||
| Date: July 29, 2004 | By: | /s/ Steven M. Neil | ||
| Steven M. Neil Chief Financial Officer |
||||